Cleveland BioLabs Announces Receipt of Letter From NASDAQ Confirming Compliance With Minimum Bid Price Requirement
February 18, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 18, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on February 12, 2015, the Company received a letter from The NASDAQ Stock Market stating that...
Cleveland BioLabs to Report Fourth Quarter and Fiscal Year 2014 Financial Results on February 24
February 17, 2015 10:34 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 17, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on February 24, 2015, it will report its financial results for the fourth quarter and fiscal...
Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents
February 11, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 11, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the issuance of several new patents for entolimod in the U.S. and other countries, further...
Cleveland BioLabs Announces Annual Meeting
February 10, 2015 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 10, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will hold its 2015 Annual Meeting of Stockholders on April 14, 2015 in Buffalo, NY...
Cleveland BioLabs to Present at 2015 BIO CEO & Investor Conference
February 05, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2015 BIO CEO & Investor Conference, February...
Cleveland BioLabs Announces $4.2 Million Financing
February 04, 2015 09:05 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 4, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has entered into definitive agreements with two institutional investors to purchase a...
Cleveland BioLabs Announces Oncology Clinical Development Update for Entolimod
January 29, 2015 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jan 29, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced updates on oncology clinical development of entolimod (previously known as CBLB502).
...
Cleveland BioLabs Announces Board Appointment
January 28, 2015 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jan 28, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Elena Kasimova of BioProcess Capital Partners to the Company's Board of...
Cleveland BioLabs Announces Results of Special Meeting of Stockholders and Reverse Stock Split
January 27, 2015 16:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jan 27, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that at a special meeting of stockholders held on January 27, 2015, stockholders authorized the...
Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod (CBLB502) as a Medical Radiation Countermeasure
January 12, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jan 12, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company received notice that the proposal application to support further development of...